Different studies have shown the association of IRF2BP2 expression in hematopoietic malignancies and solid tumors, such as breast cancer, leukemia and chondrosarcoma, through mechanisms of gene fusion and point mutations in gene coding sequences, but its exact role and the regulatory mechanism in cancers have not been explored. This evidence concerns the gene IRF2BP2 and breast carcinoma.